Next Article in Journal / Special Issue
HGF/Met-Signaling Contributes to Immune Regulation by Modulating Tolerogenic and Motogenic Properties of Dendritic Cells
Previous Article in Journal / Special Issue
Expression of Hepatocyte Growth Factor-Like Protein in Human Wound Tissue and Its Biological Functionality in Human Keratinocytes
Article Menu

Export Article

Open AccessArticle
Biomedicines 2015, 3(1), 124-137; doi:10.3390/biomedicines3010124

Anti-Differentiation Effect of Oncogenic Met Receptor in Terminally-Differentiated Myotubes

1
Department of Oncology, University of Turin, Corso Massimo D'Azeglio 52, 10126 Turin, Italy
2
Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126 Turin, Italy
3
Department of Oncology, Candiolo Cancer Institute—Fondazione del Piemonte per l'Oncologia (FPO) Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Strada Provinciale 142, Km 3.95, 10060 Candiolo, Italy
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editor: Zimmer Yitzhak
Received: 23 December 2014 / Accepted: 4 February 2015 / Published: 12 February 2015
(This article belongs to the Special Issue New aspects of the Hepatocyte Growth Factor/c-Met System)
View Full-Text   |   Download PDF [1182 KB, uploaded 12 February 2015]   |  

Abstract

Activation of the hepatocyte growth factor/Met receptor is involved in muscle regeneration, through promotion of proliferation and inhibition of differentiation in myogenic stem cells (MSCs). We previously described that the specific expression of an oncogenic version of the Met receptor (Tpr–Met) in terminally-differentiated skeletal muscle causes muscle wasting in vivo. Here, we induced Tpr–Met in differentiated myotube cultures derived from the transgenic mouse. These cultures showed a reduced protein level of myosin heavy chain (MyHC), increased phosphorylation of Erk1,2 MAPK, the formation of giant sacs of myonuclei and the collapse of elongated myotubes. Treatment of the cultures with an inhibitor of the MAPK kinase pathway or with an inhibitor of the proteasome increased the expression levels of MyHC. In addition, the inhibition of the MAPK kinase pathway prevented the formation of myosacs and myotube collapse. Finally, we showed that induction of Tpr–Met in primary myotubes was unable to produce endoreplication in their nuclei. In conclusion, our data indicate that multinucleated, fused myotubes may be forced to disassemble their contractile apparatus by the Tpr–Met oncogenic factor, but they resist the stimulus toward the reactivation of the cell cycle. View Full-Text
Keywords: HGF; Met receptor; myogenic stem cells; skeletal muscle; differentiation; proteasome; Erk1,2 MAPK HGF; Met receptor; myogenic stem cells; skeletal muscle; differentiation; proteasome; Erk1,2 MAPK
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Sala, V.; Gallo, S.; Gatti, S.; Vigna, E.; Ponzetto, A.; Crepaldi, T. Anti-Differentiation Effect of Oncogenic Met Receptor in Terminally-Differentiated Myotubes. Biomedicines 2015, 3, 124-137.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top